Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Construction in Progress of $1.5 billion for Q1 2026, down 6.94% YoY from $1.7 billion in Q1 2025, and down 4.82% sequentially from $1.6 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Construction in Progress across 12 years of filings, most recently posting $1.5 billion for Q1 2026.
- In Q1 2026, Construction in Progress fell 6.94% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 6.94% YoY), while the FY2025 annual figure was $1.6 billion, up 6.16% from the prior year.
- Construction in Progress slipped to $1.5 billion in Q1 2026, from $1.6 billion in the prior quarter.
- Over the last five years, Construction in Progress for CELG-RI reached as high as $1.8 billion in Q2 2025 and fell as low as $800.0 million in Q1 2022.
- The 5-year median for Construction in Progress is $1.2 billion (2024), against an average of $1.3 billion.
- Annual changes were most pronounced in 2022 — Construction in Progress soared 54.14% — and 2026, when it declined 6.94%.
- A 5-year view of Construction in Progress shows it stood at $1.1 billion in 2022, then grew by 2.09% to $1.1 billion in 2023, then jumped by 41.86% to $1.5 billion in 2024, then grew by 6.16% to $1.6 billion in 2025, then fell by 4.82% to $1.5 billion in 2026.
- According to Business Quant data, Construction in Progress over the past three periods registered $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | 1.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 973.00 Mn |
| Jun 30, 2022 | 850.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 764.00 Mn |
| Sep 30, 2021 | 695.00 Mn |
| Jun 30, 2021 | 565.00 Mn |